CompletedPHASE1, PHASE2NCT00384670

A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children

Studying Dengue fever

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
U.S. Army Medical Research and Development Command
Principal Investigator
MAJ Stephen J Thomas, MD, MD
Department of Virology USAMC-AFRIMS
Intervention
Dengue Vaccine Formulation 17(biological)
Enrollment
7 enrolled
Eligibility
6-10 years · All sexes
Timeline
20032004

Study locations (1)

Collaborators

GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00384670 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever

← Back to all trials